When “More Treatment” Isn’t Better: A Stage II Lung Cancer Case
Impossible d'ajouter des articles
Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.
Veuillez réessayer plus tard
Veuillez réessayer plus tard
Échec de l’élimination de la liste d'envies.
Veuillez réessayer plus tard
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
When “More Treatment” Isn’t Better: A Stage II Lung Cancer Case
-
Lu par :
-
De :
À propos de ce contenu audio
A man in his late 60s enters a lung cancer screening program and is found to have a 4.5 cm tumor—stage II by size, with high-stakes decisions ahead. The case seems to point toward modern perioperative therapy, until biomarker testing changes everything. In this episode, host Lisa Moores, MD, FCCP, is joined by CHEST Guideline Chair John Howington, MD, MBA, FCCP, and oncologist Natasha Leighl, MD, to show how multidisciplinary care—and molecular results—can reroute the entire treatment journey.
They discuss why nodal staging matters, when perioperative therapy improves outcomes, and how biomarker-driven choices can reshape the safest path, while still leaving room for shared decision-making.
Faculty
- Host: Lisa Moores, MD, FCCP
- Guideline Chair: John Howington, MD, MBA, FCCP
- Case Guest: Natasha Leighl, MD
Vous êtes membre Amazon Prime ?
Bénéficiez automatiquement de 2 livres audio offerts.Bonne écoute !
Aucun commentaire pour le moment